All of this is irrelevant from an investment standpoint with CYDY. The number of covid-19 cases won't stop approval for Leronlimab. After Leronlimab receives first approval it will stabilize CytoDyn as a pharma company and start revenue. COVID-19 will be here indefinitely and approval for Leronlimab will open the door for other ARDS.